40 lines (18 loc) · 538 Bytes

Clinical Trial Feasibility Report

Indication: EGFR-mutant non-small cell lung cancer Drug/Intervention: osimertinib Phase: Phase 2 Analysis Date: 2026-02-09

1. Patient Population

prevalence_literature: 0

2. Drug Profile

name: osimertinib

status: Novel or not in database

3. Precedent Trials

4. Safety Profile

5. Literature Evidence

article_count: 0

6. Feasibility Assessment

score: 0

interpretation: VERY LOW FEASIBILITY - Major gaps in data/precedent